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Abstract 
Alzheimer’s Disease (AD) is a growing epidemic, with a new development of AD occurring 
every 65 seconds (Alzheimer’s Association, n.d.). Previously in high-school, I completed 
surface-level research on the general similarities and differences between Canine Cognitive 
Dysfunction (CCD)—a disease with symptoms and progression pattern that parallels AD—and 
decided to continue my research more in-depth in college. I studied how β-amyloid accumulates 
in various brain regions—such as the prefrontal, occipital, entorhinal and parietal cortices—in 
canines to determine how β-amyloid accumulation is associated with the development of 
behaviors signifying cognitive decline observed in CCD and AD—such as changes in the sleep-
wake cycle, social interaction, housetraining, and general orientation—in order to understand 
how neuroscientists may be able to derive new understandings from a canine model with CCD, 
and apply them to humans with AD to develop therapies and treatments for AD. In order to 
capture a variety of perspectives when researching CCD and AD, I developed a list of questions 
to help guide and focus my research. How are canines and humans similar? How are CCD and 
AD similar? What developmental and progression parallels can be drawn? What treatments are 
effective for CCD? What treatments are effective for AD? How can shared pathologies in 
canines and humans allow for the application of CCD treatment on AD? Through my research I 
discovered that domestic canines and humans share the same environmental stressors, develop 
oxidative stress in a similar manner, and β-amyloid accumulation in the canine brain parallels β-
amyloid accumulation in the human brain. Additionally, canine response to pharmaceuticals 
mimics human response to pharmaceuticals. Because of this, conducting studies on domestic 
canines with CCD may be the best animal model for AD. I surmise that future research should be 
conducted through testing how known CCD treatments (with varying active ingredients and 
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constituents) work to suppress β-amyloid accumulation in humans. Treatments previously found 
to be successful on canines with CCD should be restudied for the purpose of observing how the 
treatment interacts with canine pathology that is shared with humans in order to better determine 
how CCD treatments can be manipulated to be efficient in treating AD. The possibility of 
synthesizing treatments through the use of laboratory canines, testing these treatments on 
domestic canines to determine effectivity, testing these treatments on laboratory rats to determine 
safety for human use, and finally manufacturing these treatments for human use could be a 
treatment development path to make implementation possible. 
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Canine Cognitive Dysfunction (CCD), Alzheimer’s Disease (AD), and β-Amyloid 
Accumulation: 
Using CCD as a Reference for the Development of AD Treatments and Therapies 
Introduction 
Alzheimer’s Disease (AD) is a progressive form of dementia with no current cure 
(Alzheimer’s Association, n.d.). 5.8 million Americans suffer from AD, with 1 in 3 seniors dying 
due to complications caused by AD (Alzheimer’s Association, n.d.). The amyloid hypothesis is a 
popular yet controversial theory that identifies β-amyloid as a key cause of AD. β-amyloid is 
small fragment of amyloid precursor protein (APP) that forms oligomers, fibrils and plaques that 
disrupt cell-to-cell communication and activate immune cells, triggering inflammation 
(Alzheimer’s Association, 2017). The amyloid hypothesis states that AD can be guaranteed to 
occur in individuals with genetic mutation in genes associated with β-amyloid production, 
causing the formation of β-amyloid plaques (Alzheimer’s Association, 2017). Very few 
treatments and antibodies have been proven to sufficiently slow β-amyloid accumulation in 
clinical trials, most notably, an aducanumab trial from 2016 was classified as the first successful 
clinical trial that evidenced slowed AD progression (Alzheimer’s Association, 2017). 
Canine Cognitive Dysfunction (CCD) is a progressive, neurobehavioral syndrome often 
referred to as ‘doggy dementia’ (Cain & Cain, n.d.). While awareness surrounding CCD’s 
existence is minimal, studies have been conducted in which CCD is used to better understand 
AD, as the two diseases are developmentally similar, and canine pathology mirrors human 
pathology. CCD is considered a good animal model for AD because canine and human 
pathology is similar, CCD and AD progress complementary to each other, and canines respond 
to pharmaceutical treatment in a fashion akin to humans, providing strong predictive validity.  
5 
CCD AS A REFERENCE FOR AD 
An example of the shared pathology between canines and humans is the development of 
β-amyloid oligomers. In the β-amyloid pathology of canines and humans, both canines and 
humans develop β-amyloid oligomers. Breydo, Kurouski, Rasool, Milton, Wu, Uversky . . . and 
Glabe (2016) conducted tests—including peptide synthesis, labeling of Aβ40 with Acrylodan, 
general Aβ preparation, Western blots, electron microscopy, FTIR, CD spectra, Raman 
spectroscopy, the determination of site-specific conformational stability, and the determination 
of global stability (p. 701)—in order to determine and further clarify the structure of Aβ 
oligomers. Breydo et al. (2016) claimed that an in-depth understanding of the structure of Aβ 
oligomers is necessary, as Aβ peptides have the ability to penetrate cell membranes and can be 
classified as a neurotoxic entity that contributes to the progression of AD development (p.700). 
Breydo et al. claimed that because fibular oligomers (FOs) and fibrils are richer in β-sheet 
stacking, they are more stable and resistant to GdnSCN denaturation, with fibrils being more 
stable than FOs) (p. 702). Breydo et al. continued that PFOs are unstructured and disordered with 
weak intermolecular interactions due to the absence of β-sheets, causing PFOs to denature at 
lower concentrations of GdnSCN than both FOs and fibrils (p. 702). Breydo et al. stated that the 
N-terminals of PFOs were completely disordered, while C-terminals indicated the presence of 
antiparallel β-barrels (p. 705). Zahs and Ashe (2013) supported Breydo et al. (2016)’s claims, 
stating that identifying the oligomer that causes amyloid cascading is integral to developing 
treatments and therapies to prevent AD. Research regarding β-amyloid oligomer structure is 
critical in determining possible therapies, as it is necessary to establish the cause of β-amyloid 
oligomer deposition in order to determine options to block this spreading. Researchers must 
identify the structure of β-amyloid oligomers, as it would be extremely difficult to develop 
treatments and therapies to combat its neurotoxicity. Identifying the oligomer responsible for 
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initiating amyloid growth in canines with CCD could be useful when developing treatments and 
therapies for AD, as oligomer functions may be monitored more easily, and treatments and 
therapies may be tested and observed before implementation on a test subject with similar 
pathology and pharmacological responses to humans. In “A Canine Model of Human Aging and 
Alzheimer's Disease,” Head (2013) conducted a study observing laboratory canines completing a 
set of complex tasks to determine how behavior dysfunction is linked to the brain’s cortices. 
Head claimed that β-amyloid oligomers are inversely related to the total amount of Aβ 
accumulation in the brain in the study. 
 Because canines share a common environment and environmental stressors, both species 
develop oxidative stress in a similar manner, contributing to the similar manner in which both 
species accumulate β-amyloid. β-amyloid accumulation in the prefrontal, entorhinal, and 
occipital cortices in canines with Canine Cognitive Dysfunction (CCD) parallels that of humans 
with Alzheimer’s Disease (AD), and canines’ response to pharmaceuticals closely resembles that 
of humans, making CCD the ideal reference model to study the early stages of AD, and a solid 
foundation to begin developing and testing new treatments and therapies. A canine model may 
prove to be helpful when synthesizing new treatments, however new treatments could be tested 
first on laboratory rats due to ethical concerns. This is especially apparent in the modern ‘cruelty-
free’ climate, in which drug manufacturers along with cosmetic companies have been criticized 
by organizations (such as PETA) for preforming preliminary testing of products on animals such 
as rabbits. Texas A&M University faced harsh backlash from the general public after it was 
discovered that live canines were being used to study Duchenne Muscular Dystrophy (DMD) 
(People for the Ethical Treatment of Animals, n.d.). In order to comply with the ethical demands 
of the public, preliminary testing could be conducted on laboratory rats to determine if new 
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treatments are safe for use on canines before secondary testing is conducted on laboratory 
canines and domestic canines.  
By determining how β-Amyloid accumulates in various brain regions—such as the 
prefrontal, occipital, entorhinal and parietal cortices—in canines to determine how β-amyloid 
accumulation is associated with the development of behaviors signifying cognitive decline 
observed in CCD, and AD—such as changes in the sleep-wake cycle, social interaction, 
housetraining, and general orientation, neuroscientists may be able to derive new understandings 
from a canine model and apply them to AD to develop therapies and treatments for AD. Newly 
developed treatments could be developed using canine pathology, tested on laboratory rats to 
determine if the treatment can be safely administered to canines and humans, tested on 
laboratory canines with CCD to observe how the treatment interacts with canine pathology, 
tested on domestic canines to observe any differences in effectiveness and function, and human 
trials can be conducted to determine if any further manipulation of the treatment is needed.  
Differentiating Between Being Aged vs. Impaired 
Because a definitive line between having the status of aged or impaired in canines and 
humans has not been exclusively defined, treatments and therapies aimed to slow CCD and AD 
progression are not prescribed during early stages of each respective disease, lowering the ability 
of the treatments and therapies to work efficiently. Establishing a specific boundary to mark 
when a canine or human is merely aging or suffering from cognitive impairment or CCD/AD is 
necessary when developing treatments and therapies to separate gentler, precautionary measures 
from harsher, more aggressive treatment intended to be used on those determined to be impaired. 
Madari, Farbakova, Katina, Smolek, Novak, Weissova, . . . and Zilka (2015) conducted a 
study with 300 canines (85 ineligible for observation) in which canines were scored from zero to 
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five (zero meaning abnormal behavior was never observed, and five meaning abnormal behavior 
was observed several times within a week) for 17 items separated into 4 categories; special 
orientation, social interactions, sleep-wake cycles and house soiling (p.139). Madari et al. (2015) 
identified the stages of CCD as mild cognitive impairment, moderate cognitive impairment, and 
severe cognitive dysfunction, and developed an assessment to measure the severity and 
progression of CCD named CADES (canine dementia scale) (p.138). Madari et al. claimed that 
the development of the CADES scale for canines was necessary due to the lack of information 
known about CCD stages and phenotypic variability (p.138). Colliot, Chételat, Chupin, 
Desgranges, Magnin, Benali, … and Lehéricy (2008) recognized a similar problem in 
distinguishing between humans with AD and humans with mild cognitive impairment (MCI). In 
their study, Colliot et al. (2008) segmented the hippocampi of 25 patients with AD, 24 patients 
with MCI, and 25 healthy elderly and measured the average hippocampal volume for each group 
to distinguish between patients with AD, patients MCI, and elderly controls (p. 195). Colliot et 
al. assessed the accuracy of automated hippocampal volumetry in response to the lack of 
definition between AD individuals and MCI, and determined that hippocampal volume loss was 
an accurate way to distinguish between those with AD and MCI, as 84% of AD patients were 
correctly classified by analyzing hippocampal volume loss (p. 200).  
Brustrom and Ober (1998) conducted a study in which 40 elderly normal adults and 28 
individuals with AD were measured for global cognitive functioning, memory, use of memory 
strategies, memory strategy efficacy, and depressive symptomatology in order to determine 
predictors of perceived memory impairment (p.404). Brustrom and Ober aimed to distinguish 
between aged brains and AD through a methodologically qualitative approach, as memory 
strategies and efficacy were measured in the elderly (average age of 75) in order to define the 
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difference between aging/MCI individuals versus AD individuals (p.404). Brustrom and Ober 
concluded that while previous studies connecting objective and perceived memory have not been 
concrete in their findings, the study found that those with less severe AD are more likely to 
acknowledge deficits in memory when compared to those with more severe AD, and that those 
who are aging report memory consistent with their memory test scores (p. 408). Brustrom and 
Ober contest that further research should be done concerning the connections between objective 
and perceived memory in order to determine whether it may be used as a solid defining factor to 
separate those who are aging from those with AD, especially as qualitative measures to define 
aging and AD (p. 409). 
Defining set standards to separate whether a canine or human is cognitively impaired 
rather than aging may significantly impact the efficiency of a treatment or therapy that is 
prescribed. Because there is not a definite line separating the loss of cognitive function due to 
natural aging versus having the status of being cognitively impaired, there are many missed 
opportunities to treat early stages of CCD and AD. Behavioral markers for CCD and AD—such 
as changes in the sleep-wake cycle, social interaction, housetraining, and general orientation—
may be overlooked and attributed to natural aging, despite these symptoms being associated with 
early stage progression of CCD and AD. The missed diagnosis of early stages of CCD and AD, 
and the misdiagnosis of CCD and AD as natural aging eliminates the possibility of introducing 
less aggressive therapies—such as increasing antioxidant content in the diet through supplements 
such as Aktivait (for canines)—and treatments—such as Donepezil, Galantamine, and 
Rivastigmine (for humans)—to those affected in order to slow progression of CCD and AD and 
suppress behavioral symptoms. 
Similarities Between Human and Canine Pathology 
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Because canines and humans share similar general pathologies, similar β-amyloid 
pathologies, and display complementary signs of oxidative damage due to sharing the same 
environmental stressors, canines and humans may share the same factors that contribute to CCD 
and AD and progress each disease.  
 β-amyloid peptides share nearly identical pathology in canines and humans. In “Plasma 
Β-Amyloid Peptides in Canine Aging and Cognitive Dysfunction as a Model of Alzheimer's 
Disease,” González-Martínez, Rosado, Pesini, Suárez, Santamarina, García–Belenguer, . . .  and 
Sarasa (2011) conducted a study with 88 canines separated into four groups of (young, middle-
aged, cognitively unimpaired aged, and cognitively impaired aged) (p.591).  González-Martínez 
et al. (2011) defined young as one to four-year-old canines, middle-aged as five to eight-year-old 
canines, and cognitively impaired or unimpaired as less than nine-year-old canines (pp. 591). 
González-Martínez et al. stated that there were nine young canines, ten middle-aged canines, 31 
cognitively unimpaired canines, and 38 cognitively impaired canines observed (88 canines total) 
(p.591). González-Martínez et al. identified sleep-wake cycle, social interaction, housetraining, 
and orientation as key areas of cognitive deficit in canines with cognitive impairment, measured 
levels of plasma Aβ1-42 and Aβ1-40 in canines with and without CCD, and hypothesized that 
the respective Aβ levels would correlate with the canines’ level of cognitive impairment (p. 590). 
González-Martínez et al. claimed that β-amyloid peptide deposition present in CCD parallel 
plasma β-amyloid, a biomarker for AD, as both evidence similar neurodegeneration and 
oxidative damage patterns (p. 590). González-Martínez et al. identified plasma Aβ1-42 as a 
relatively controversial biomarker that specifically distinguishes between non-cognitively 
impaired and mildly impaired humans (p. 591), and created a study to observe the Aβ1-42 
proposed biomarker in companion canines. González-Martínez et al. asserted that the cognitively 
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impaired group of canines had a higher level of Aβ1-42 accumulation than the cognitively 
unimpaired group of canines, and claimed that while Aβ1-42 levels were high in cognitively 
impaired canines, the mildly impaired canines actually had the highest level of Aβ1-42 
accumulation (pp. 594). González-Martínez et al. hypothesized that the decrease in Aβ1-42 
levels in cognitively impaired canines aged nine years or more may be caused by increasing 
brain amyloid deposition, however, despite the decrease of Aβ1-42 in relation to age, mildly 
impaired canines had higher Aβ1-42 levels than both unimpaired and severely impaired canines 
(p. 594). González-Martínez et al. claimed that the amyloid hypothesis, often used to explain the 
development of AD, is reflected in both mild CCD and mild AD when observing Aβ1-42 
accumulation, making mild CCD a good reference model for mild AD (p.594). Likewise to 
González-Martínez et al., Head (2013) identified the Aβ1-42/Aβ1-40 ratio in cerebrospinal fluid 
to be a good indicator of cognitive decline (p. 1386) in canines and humans.  
 The identification of Aβ1-42 as a potential biomarker in both CCD and AD could prove 
to be useful in the development of treatments for CCD that can be manipulated to treat for AD. 
In order to create effective treatments for any disease or condition, researchers (in the case of 
CCD and AD—neuroscientists) must first establish the cause(s) and biomarkers for the disease 
or condition. The establishment of biomarkers provides a foundation for neuroscientists to 
develop a treatment from, as the primary function of the treatment will most likely target the 
biomarkers of the disease or condition. The identification of a common biomarker between CCD 
and AD, Aβ1-42, should make it easier to develop a treatment that is applicable to canines with 
CCD and humans with AD, as the treatment would only have to target one shared biomarker 
(Aβ1-42) rather than multiple different biomarkers. Because Aβ1-42 exists as a potential 
biomarker in CCD and AD, a treatment could be developed that specifically targets Aβ1-42 in 
12 
CCD AS A REFERENCE FOR AD 
order to diminish the accumulation of Aβ1-42, subsequently slowing CCD or AD progression 
during early stages. 
Head (2013) conducted studies with laboratory beagles with a median lifespan of 13.9 
years (p.1384). Head identified beagles under five years old to be similar to humans under 40 
years old, beagles five to nine-years-old as humans between 40-60 years old, and beagles over 
nine years as humans 66 years or older (pp. 1384). Head claimed that molecular cascades—such 
as accumulation of β-amyloid in both the cerebral vasculature and diffuse plaques—advance 
cognitive degeneration, as seen in mild CCD and AD (p. 1384). Head argued that canine models 
have more predictive validity when applying CCD test results on humans due to the extreme 
similarities in pathology, including the identical amino acid sequences coding for Aβ in canines 
and humans, and the shared presence of Aβ precursor protein APP in both canines with CCD and 
humans with AD (p. 1384). Head claimed that the spontaneous development of white matter is 
consistent in both AD and CCD, which is linked to laminin immunoreactivity deficits and 
increased iron deposits (p. 1385). Head asserted that a loss of myelin observed in aging dogs may 
leave the frontal cortex vulnerable to white matter, progressing CCD significantly (p. 1385).  
In “Canine Cognitive Dysfunction and Alzheimer’s Disease – Two Facets of the Same 
Disease,” Prpar Michevc and Majdič (2019) claimed that β-amyloid accumulation occurs 
frequently in cerebral amyloid angiopathy (CAA), which is the accumulation of β-amyloid in 
blood vessels of the cerebral cortex (p. 6). Similarly, Head (2013) argued that CAA is observed 
in similar frequency in both canines and humans (p. 1386). Head stated that CAA may create 
vulnerability in the occipital cortex, leading to impaired vascular function and 
microhemorrhages, in both canines and humans (p. 1386).  
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 While canine and CCD pathology mirrors human and AD pathology nearly perfectly, 
there are minimal differences that should be taken into account when using canines and CCD as 
a reference for humans and AD. Schütt, Helboe, Pederson, Waldemar, Berendt, and Pederson 
(2016) conducted a study in which they observed 15 canine brains ranging from normal 
cognitive function, mild cognitive dysfunction, or CCD, observed amyloid-β plaque deposition, τ 
pathology, and inflammatory markers present in the prefrontal cortex, and compared 
observations from cognitively impaired canine brains to the brain of a young dog, and brain 
sections from AD patients (control). Schütt et al. (2016) stated that distinct τ protein 
accumulation and histology in canines with CCD was inconclusive, and that no neuritic plaques 
were found in the canine brains studied, meaning cortical Aβ deposition was denoted as a diffuse 
subtype. Despite this, Schütt et al. concluded the study by stating that CCD is a model that could 
provide more insight into AD, especially when concerning Aβ pathology and progression during 
early AD stages. 
Because canines and humans share similar pathology, treatments could be tested on 
canines with CCD to observe how the treatment could interact with pre-existing pathology. The 
observations of how treatments interact with the pathology of a canine with CCD could be used 
to predict how the treatment may interact with the pathology of a human with AD. The testing of 
new treatments on canines with CCD could prove useful in observing pathological interactions—
such as how a treatment may suppress β-amyloid accumulation—to determine if a treatment is 
effective in slowing CCD and AD progression. If a treatment is not effective in slowing CCD 
progression in canines, there is a high chance that the treatment will not be effective in slowing 
AD progression in humans. Because canines and humans share similar pathology, canines with 
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CCD provide predictive validity on how effective a treatment may be when introduced to 
humans with AD. 
Canines and Humans Share the Same Environment and Environmental Stressors 
Because canines and humans share the same environment and environmental stressors 
they may subsequently display similar patterns in oxidative damage development. Canines and 
humans are socially dependent animals that must adapt to adhere to the changing social 
environment, this creates stress that can cause oxidative damage and contribute to the 
progression of CCD and AD. Because canines and humans develop oxidative damage 
complementary to each other, domestic canines may be the best canines to conduct studies to use 
CCD as a reference for AD. 
Oxidative damage and neuroinflammation contribute significantly to the development of 
β-amyloid deposition, fueling the progression of CCD and AD. While it is most common for 
researchers investigating CCD and AD to use laboratory canines, it may be more beneficial to 
use domestic or companion canines because domestic canines share a common environment with 
humans. Therefore, companion canines and humans may share the same environmental stressors 
that contribute to oxidative damage and neuroinflammation. In “Identification and Management 
of Cognitive Decline in Companion Animals and the Comparisons with Alzheimer Disease: A 
Review,” Cory (2013) stated that few studies have been conducted with companion animals 
rather than laboratory animals, and proposed that future studies should consider varying genetic, 
cognitive, and environmental factors in order to more similarly reflect AD environments (p. 
292). Cory stated that CCD shares similar development patterns of β-amyloid to AD, and 
hypothesized that the development of β-amyloid is caused by neuroinflammation and oxidative 
stress caused by the environment (p. 292). Cory claimed that canine sociability mirrors human 
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sociability, and contended that studies conducted on laboratory dogs fail to capture these social-
environmental factors (cognitive challenges) due to the controlled environment laboratory 
canines are studied in (p. 292).  
The use of laboratory canines excludes environmental stressors that cause oxidative 
damage, while canines that share the same environment as humans mirror the oxidative damage 
seen in humans (due to the shared environmental stressors). Cory (2013), and González-Martínez 
et al. (2011) claimed how the use of laboratory canines may limit the possible connections that 
could be made between CCD and AD. The development of oxidative stress is often attributed to 
environmental stressors, so using domestic canines to observe progression would serve as a more 
accurate model due to its increased similarity (González-Martínez et al., 2011). Since laboratory 
canines do not share the same environmental stressors as humans due to the extremely controlled 
conditions in labs, the use of domestic canines instead of laboratory canines may prove to be 
more useful. Canines with oxidative damage may respond differently to treatments and therapies 
when compared to canines without oxidative stress, so it is important to conduct studies 
concerning CCD on domestic canines as it would make results easier to translate to AD 
application, especially when considering the fact that domestic canines are exposed to the same 
environmental stressors as humans.  
Similar Behavioral Changes in Humans and Canines 
Because canines and humans share similar pathology and environmental stressors, both 
species exhibit similar behavioral deficits—such as reversal learning failure, visuospatial 
difficulties, and acquisition and recognition decline—as CCD or AD progresses respectively.  
Cory (2013) stated that in both canines and humans, β-amyloid accumulation in the 
cerebral cortex may be linked to behavioral changes (p. 294). Cory stated that specifying 
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behavioral markers to identify as cognitive decline may increase the ability to diagnose AD and 
CCD earlier in progression, and named specific behaviors—such as decreases in adaptability, 
and increases in anxiety or repetitive behavior—as possible markers (p. 292). Cory identified 
memory, problem-solving ability, and adaptability to be main areas of decline in AD and CCD, 
along with social withdrawal (p. 293). Cory claimed the behavioral changes in canines are 
repetitive and incomplete behaviors, patterns which may repeat anywhere from within minutes to 
hours throughout a given day (p. 293). Cory claimed that one key behavioral change in the 
diagnosis of CCD and AD is changes in sleep-wake cycles (p. 294), and identified 
overattachment and isolation as two main factors relating to social changes that may be used to 
diagnose AD and CCD. Cory claimed that in both CCD and AD, canines and humans will fail to 
complete previously learned tasks—such as eating, potty-training, and moving around a known 
environment (p. 294). Cory asserted that as each respective disease develops, all factors build up 
to cause a change in behavior and character (p. 294). 
 González-Martínez et al. (2011)—Like Cory (2013)—identified four key areas of 
cognitive deficit in CCD canines; sleep-wake cycle, social interaction, housetraining, and 
orientation (pp. 590). González-Martínez et al. stated that the 2 key areas with the most reported 
dysfunction in their cognitive status questionnaire—which was completed by the owners of the 
companion canines observed in the study—were sleep-wake cycle and socio-environmental 
interactions (pp. 594). 
Because canines and humans share four common, key areas of cognitive decline—
changes in the sleep-wake cycle, social interaction, housetraining, and spatial orientation—
treatments could be developed to target the key areas of decline and be implemented in canines 
with CCD and humans with AD. 
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β-Amyloid Accumulation in Different Brain Regions 
Because β-amyloid accumulates in multiple brain regions—such as the prefrontal, frontal, 
occipital, parietal, and entorhinal cortices—each region β-amyloid accumulates in causes a 
specific aspect of cognitive dysfunction to occur—such as visual discrimination deficits, sleep-
wake cycle disruptions, and retention errors—depending on which brain region evidenced β-
amyloid accumulation. 
Cummings, Head, Afagh, Milgram, and Cotman (1996) conducted a study in which 
eleven purebred beagles from New York and nine mixed breed mongrels from Canada were 
observed for reward approach and learning approach learning, followed up with discrimination, 
reversal, object recognition and spatial learning testing in order to determine a correlation with 
Aβ accumulation (p. 12). Cummings et al. (1996) claimed that declines in overall cognitive 
function as well as in behavioral tasks, such as orientation and recognition, were both correlated 
with Aβ accumulation (p. 18). Head (2013) came to a similar conclusion, and specified that tasks 
associated with the prefrontal cortex, such as reversal learning and visuospatial working memory 
are shown to decline in canines with CCD (p. 1384). Head claimed that memory decline as a 
function of age may be observed through acquisition, such as object recognition and spatial 
learning, and occurs early in the aging process in, when canines are approximately six or seven 
years old (p. 1385). Head asserted that each loss of function in canines may be attributed to 
cognitive decline in a specific domain of the brain (i.e. prefrontal decay is associated with 
reversal learning and visuospatial working memory decline) (p. 1385). Head stated that cortical 
atrophy and ventricular widening are consistent products of cognitive decline, while decline in 
other domains in the brain may vary, such as in prefrontal cortex and the hippocampus (p. 1385).  
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When determining treatment options, connecting the cognitive deficiencies associated 
with CCD and AD (reversal learning, acquisition, recognition, visuospatial memory, etc.) with β-
amyloid accumulation in the prefrontal, entorhinal and occipital cortices is critical when 
determining the appropriate prescription for canines and humans alike. Treatments and therapies 
target specific brain regions (such as the prefrontal, entorhinal, and occipital cortices) and work 
to suppress symptoms associated with each region’s decline (such as reversal memory failure, 
recognition decline, etc.). Identifying the role β-amyloid plays in these cortices to cause these 
cognitive deficiencies in canines is necessary to begin making hypotheses concerning how CCD 
treatments may be manipulated to be implemented in AD patients.  
A previous study conducted by Head, Callahan, Muggenburg, Cotman, and Milgram 
(1998)—in which 24 canines (ages ranging from 2.4 years to 13.3 years old) being kept 
individually in wooden boxes were observed in order to determine the effect of side and object 
preference on the accumulation of β-amyloid and behavioral dysfunction by the use of two 
objects and three food wells (p. 416)—elaborated on the prefrontal, entorhinal, and occipital 
cortices’ and lobes’ roles in instances of cognitive decline in canines. Head et al. (1998) 
classified canines five or less years old as young, canines six to nine years old as middle-aged, 
and canines ten or more years old as old (p. 416). Head et al. claimed that β-amyloid 
accumulation in the prefrontal cortex was significantly associated with the impairment of 
reversal learning, β-amyloid accumulation in the entorhinal cortex was significantly associated 
with the impairment of size-discrimination learning, and β-amyloid accumulation in the parietal 
and entorhinal cortices was significantly associated with reward-approach learning (p. 420). 
Head et al. determined that Aβ accumulation in the occipital lobe is associated with impairment 
in object-discrimination (p. 420). A study conducted by Head, McCleary, Hahn, Milgram, and 
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Cotman (2000)—in which vibratome sections from 40 canines (one group of 20 canines aged 4.5 
to 15.3-years-old, and one group of 20 canines aged 6.7 to 17.8-years-old) were collected from 
the dorsolateral prefrontal cortex, entorhinal cortex, occipital cortex and parietal cortex in order 
to measure Aβ accumulation and determine a correlation between Aβ deposition in brain cortices 
and behavioral dysfunction (p. 90)—provided a timeline for β-amyloid accumulation in these 
cortices. Head et al. (2000) stated that Aβ deposition in the prefrontal cortex frequently began 
around the age of nine, while Aβ deposition in the parietal, occipital, and entorhinal cortices 
began around the age of 14, with the lowest Aβ deposition occurring in the parietal cortex (p. 
92).  
Head et al. claimed that Aβ deposition relationship in the entorhinal and parietal cortices 
was virtually the same, while Aβ deposition was significantly the highest in the prefrontal cortex 
and significantly the lowest in the occipital cortex (p.92). Head et al. claimed that the pattern of 
Aβ deposition found in canines—beginning in the prefrontal cortex, spreading to the entorhinal 
and parietal cortices, and finally the occipital cortex—is consistent with the Aβ deposition 
pattern found in humans (p.94). Head et al. stated that canines under 11 years resembled Aβ 
deposition patterns of those in Stage A of Braak and Braak’s (1991) staging scheme—a study in 
which the stages of AD were clarified—with older canines displaying Aβ deposition in the 
cortical regions resembled those in Stage B, and older canines displaying Aβ deposition in 
subcortical regions resembled those in Stage C (canines in Stage B and C were diagnosed with 
clinical dementia). Head et al. elaborated that only a subset of canines 14 years or younger will 
experience behavioral deficits associated with the hippocampal or entorhinal cortex functions, 
and asserted that intervention targeted towards the prefrontal cortex would be best implemented 
before the age of eight in canines (p. 95). 
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Schütt et al. (2016) contested that Aβ pathology in the prefrontal cortex is positively 
correlated with age, rather than the severity of cognitive decline, bringing into question if CCD 
and AD are guaranteed with age (p. 433). Contrary to Schütt et al., Head (2013) claimed that 
cognitive decline is not guaranteed as a result of aging in humans or canines. Both Schütt et al. 
(2016) and Head (2013) stated that more research should be conducted with the prefrontal 
cortex, along with other brain regions (such as the entorhinal, parietal, and occipital cortices) that 
contribute to behavioral dysfunction associated with CCD and AD (such as visuospatial 
disfunction and memory decline). 
Making connections between β-amyloid accumulation in different brain regions and 
corresponding cognitive decline behaviors in canines and humans may be substantially beneficial 
when trying to determine if CCD treatments will be applicable to the same brain regions and 
behaviors or if they will have a different or no effect. AD treatments are often prescribed to 
decrease the intensity or frequency of a specific behavior associated with AD—such as size-
discrimination, reward-approach and object-approach learning decline. Gaining familiarity with 
β-amyloid accumulation in the canine brain cortices to determine if new treatments and therapies 
would target the same brain cortex—and subsequently the same behavior—could be immensely 
useful as it provides a better understanding on how new treatments may differ in function in 
canines and humans. Determining if a treatment targets the same brain cortex in canines and 
humans may influence the amount of manipulation needed to make the treatment applicable in 
CCD and AD while performing the same function and offering the same benefits. Future studies 
should consider developing connections between how canine brain cortices react to constituents 
of CCD treatments in comparison to how canine brain cortices react to constituents of AD 
treatments. Establishing constituents that target the same brain cortex and provide the same 
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benefits in canines with CCD and humans with AD could make the synthetization of new 
treatments that are effective in treating behavioral deficits in CCD more easily applicable to the 
treatment of the same behavioral deficits in AD. 
Application of CCD Treatments for Canines on Humans with AD 
Because canines share general and β-amyloid pathology and respond to medicinal 
ingredients akin to humans (due to paralleling genomes), medication that is used to treat CCD 
may be manipulated and applied to AD. 
 In “Nutritional Supplementation in Cases of Canine Cognitive Dysfunction—A Clinical 
Trial,” Heath, Barabas, and Craze (2007) implemented the nutritional supplement Aktivait into 
the diets of 20 canines to observe its effects on traditional CCD behaviors in order to compare 
the therapeutic effects of Aktivait against 24 canines being administered a placebo (p. 287). 
Heath, Barabas, and Craze hypothesized that the similar pathology between CCD and AD 
suggests that treatments that work for one disorder could possibly be applied to the other with 
shared success (p. 284). Heath, Barabas, and Craze identified single ingredient supplements, 
such as fruit derived polyphenolics which have high antioxidant activity, as an example of 
treatment that has observed success in relieving AD symptoms that could be implemented in 
CCD canines, and asserted that nutritional manipulation in the form of adding antioxidants to the 
diet may improve behavioral defects caused by CCD and AD (p. 285). Heath, Barabas, and 
Craze identified the antioxidants in Aktivait, such as N-acetyl cysteine, α-lipoic acid, Vitamins C 
and E, L-carnitine and Co-enzyme Q10, DHA and EPA, and phosphatidylserine (p. 285). Heath, 
Barabas, and Craze claimed that vitamins C and E, and NAC protect against oxidative stress, 
while Q10, selenium and α-lipoic acid are efficient antioxidants (p. 293). Heath, Barabas, and 
Craze claimed that the introduction of L-carnitine, acetyl-L-carnitine, and α-lipoic acid resulted 
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in improved overall cognitive function, and should be used as a combination (p. 293). Heath, 
Barabas, and Craze claimed that behavioral errors previously observed in tasks such as sleep-
wake cycle, recognition, and house-training were decreased after the introduction of Aktivait (p. 
293). This study by Heath, Barabas, and Craze provides valuable information regarding 
antioxidant effects on AD and CCD, and may be implemented as a less harsh, more assessable 
and easily introduced treatment. The connection of each of the constituents of Aktivait (N-acetyl 
cysteine, α-lipoic acid, Vitamins C and E, L-carnitine and Co-enzyme Q10, DHA and EPA, and 
phosphatidylserine) to a specific brain region—such as the parietal, prefrontal, or occipital 
cortices—is needed in order to fully grasp how nutritional therapy may improve AD and CCD 
symptoms—such as visuospatial, recognition, and acquisition behavioral deficits. Future studies 
could be conducted with the introduction of Aktivait into a human diet to determine whether the 
same benefits would be observed, and how the concentration of constituents can be manipulated 
to observe a more effective treatment option in humans. 
Similar to Heath, Barabas, and Craze (2007)—Cory (2013) claimed in “Identification and 
Management of Cognitive Decline in Companion Animals and the Comparisons with Alzheimer 
Disease: A Review,” that canines show a positive response to cerebral perfusion, anxiolytic 
agents, antioxidants, lifetime cognitive enrichment, and behavioral training (pp. 292). Cory 
claimed that by participating in neuroprotection and neurogenic practices through cognitive 
stimulation, canines and humans may have a lessened chance of developing CCD of AD 
respectively (p. 296). Cory stated that cognitively and socially rich environments positively 
correlate with maintaining cognitive ability before and after preclinical symptoms have begun to 
occur (p. 296). Cory continued that as long as cognitively rich environments are introduced in an 
easing manner without exacerbating clinical symptoms, they would be beneficial in addition to 
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medication or lifestyle modifications (p. 296). Cory stated that while biomarkers to identify CCD 
and AD early on exist, pharmacological treatment can only be prescribed when symptoms hinder 
a patient’s ability to function (p .297). Cory identified some pharmacological treatments such as 
memantine, which reduces neuronal death while maintaining physiological function (moderate to 
severe AD), donepezil which provides short-term solutions concerning cognitive function by 
increasing acetylcholine by inhibiting acetylcholinesterase, propentofylline, which increases 
blood flow through the brain and improves social behavior, diazepam and fluoxetine which 
improve overall function, and selegiline which inhibits monoamine oxidase-B (p. 299). Cory 
claimed that while nutritional and pharmacological treatments may improve a patient’s 
physiological wellbeing post-diagnosis, nutraceuticals may serve as preventative strategies in the 
mild stages of AD and CCD (p. 299). Cory stated that because the relationship between 
physiology and behavior is so convoluted, a balance between neuropathophysiological and 
epidemiological treatment and therapy must be achieved in order to slow progression and treat 
symptoms most effectively (p. 298). Cory asserted that additionally, recognizing that 
pharmacological treatment of each disease in its earlier stages is the key to success, and studying 
the differences in pharmacological effectiveness on both diseases and species is also necessary 
(p. 299). Conducting studies in which canines are treated with pharmaceuticals—such as 
donepezil and fluoxetine—and have neuroprotective practices—such as an antioxidant 
supplement and cognitive stimulation—implemented simultaneously may assist in determining 
how the effectiveness of pre-existing treatments can be enhanced. Finding a balance between 
pharmaceutical treatment and neuroprotective practices in canines with CCD could provide a 
better understanding for the balance of pharmaceutical treatment and neuroprotective practices in 
humans with AD. 
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 In “Canine Cognitive Dysfunction Syndrome: Prevalence, Clinical Signs and Treatment 
with a Neuroprotective Nutraceutical,” Osella, Re, Odore, Girardi, Badino, Barbero, & 
Bergamasco (2007) observed 124 canines for the prevalence of clinical signs of CCD in aged 
canines, and conducted an open-label clinical pilot trial to determine whether clinical signs of 
CCD decreased with the implementation of neuroprotective nutraceutical Senilife (p. 299). 
Osella et al. (2007) claimed that canines must demonstrate one or more signs associated with 
CCD—such as spatial disorientation and confusion, learning and memory disorders, inability to 
recall previously learned commands, repetitive activity or hypoactivity, difficulties in social 
interaction, modified sleeping-wake patterns, states of anxiety or restlessness, change in appetite, 
decline in personal cleanliness, and reduced perception of response to stimuli—to be officially 
diagnosed with CCD (p.300). Osella et al. identified 39 items to be tested, which were grouped 
as disorientation (nine items), socio-environmental interaction (13 items), sleep–wake cycles 
(four items), house soiling (six items) and general activity (seven items) (p.301). Osella et al. 
stated canines introduced to Senilife showed a marked improvement CCD clinical signs (p.306). 
Osella et al. identified the constituents of Senilife as phosphatidylserine (PS), standardized 
Gingko bilobaextract (EGb), pyridoxine and d-alpha-tocopherol (p. 306). Osella et al. claimed 
that the implementation of PS in human patients and laboratory animals improved learning and 
memory, and it has been proven to be safe through canine testing and human testing (p. 306). 
Osella et al. stated that EGb stimulates the cholinergic, serotonergic, noradrenergic and 
glutaminergic system, inhibits MAO A and B, increases dopamine levels, protects the neurons 
against apoptosis induced by β-amyloid protein, increases brain metabolism, and promotes short-
term retention of spatial memory in laboratory canines (p.306). Osella et al. claimed that these 
benefits may be reproduced when implemented in AD patients. Future studies should attempt to 
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confirm Osella et al.’s claim that Senilife benefits may be reproduced in AD patients by 
implementing Senilife into the diets of humans with AD. Concentrations of the constituents of 
Senilife should be manipulated in canines with CCD order to determine predictions for the 
highest efficiency rates in humans with AD. 
 Laboratory canines and domestic canines may be used as a reference to test newly 
synthesized treatments for AD. Newly developed treatments could first be developed considering 
canines pathology, and tested on laboratory rats to determine if the treatment can be safely 
administered to canines and humans. The treatment could then be tested on laboratory canines 
with CCD in order to observe how the treatment interacts with canine pathology (which is 
strikingly similar to human pathology), and β-amyloid pathology. The treatment could move to 
testing on domestic canines in order to observe any differences in effectiveness and function 
because of oxidative damage present in domestic canines (caused by environmental stressors 
shared by humans). Finally, human trials can be conducted to determine if any further 
manipulation of the treatment needs to be conducted in order to maintain consistent function and 
efficiency across species. The efficiency of the treatment should be heavily tracked from the 
laboratory rat test phase to the human trial test phase.  
Conclusion 
 Canines with CCD share similar general and β-amyloid pathology, accumulate β-amyloid 
in the parietal, prefrontal, entorhinal, and occipital cortices in a similar manner, display common 
behavioral deficits, and respond to pharmaceuticals in a complementary fashion to humans with 
AD. Because of this, canines with CCD are the best animal reference to study the progression of 
AD, and provide a foundation for the synthetization of new treatments with predictive validity. 
Treatments for canines with CCD—such as Aktivait—should be researched further to determine 
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how constituents from CCD treatments can be manipulated for implementation in humans with 
AD. New treatments for AD could be developed using laboratory canines (due to canines and 
humans sharing similar pathology), have preliminary testing conducted using laboratory rats (to 
determine if the treatment can be safely implemented in canines and humans), secondary testing 
on domestic canines (to observe how the treatment interacts with oxidative damage caused by 
environmental stressors that are shared with humans), and finally, complete human trials to 
establish the level of efficiency of the new treatment. From this process, the new treatment may 
be manipulated in any phase to enhance the efficiency of the treatment until the maximum 
















CCD AS A REFERENCE FOR AD 
References 
Alzheimer’s Association (AA). (2017). Beta-amyloid and the amyloid hypothesis. Retrieved 
from https://www.alz.org/national/documents/topicsheet_betaamyloid.pdf 
Alzheimer’s Association (AA). (n.d.). Facts and figures. Retrieved from 
https://www.alz.org/alzheimers-dementia/facts-figures 
Braak, H., & Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. Acta 
Neuropathologica, 82(4), 239-259. doi:10.1007/bf00308809 
Breydo, L., Kurouski, D., Rasool, S., Milton, S., Wu, J.W., Uversky, V.N., . . . & Glabe, C.G. 
(2016). Structural differences between amyloid β oligomers. Biochemical and 
Biophysical Research Communications, 477(4), 700-705. doi:10.1016/j.bbrc.2016.06.122 
Brustrom, J.E., & Ober, B.A. (1998). Predictors of perceived memory impairment: Do they 
differ in Alzheimer’s Disease versus normal aging? Journal of Clinical and Experimental 
Neuropsychology, 20(3), 402-412. doi:10.1076/jcen.20.3.402.815 
Cain, S., & Cain, M. (n.d.) Dogs get dementia? Yes, they do… Retrieved from 
https://vth.vetmed.wsu.edu/specialties/behavioral/ccd-dog-dementia 
Colliot, O., Chételat, G., Chupin, M., Desgranges, B., Magnin, B., Benali, H.… & Lehéricy, S. 
(2008). Discrimination between Alzheimer Disease, mild cognitive impairment, and 
normal aging by using automated segmentation of the hippocampus. Radiology, 248(1), 
194-201. doi:10.1148/radiol.2481070876 
Cory, J. (2013). Identification and management of cognitive decline in companion animals and 
the comparisons with Alzheimer Disease: A review. Journal of Veterinary Behavior: 
Clinical Applications and Research, 8(4), 291-301. doi:10.1016/j.jveb.2012.08.001 
28 
CCD AS A REFERENCE FOR AD 
Cummings, B.J., Head, E., Afagh, A.J., Milgram, N.W., & Cotman, C.W. (1996). β-amyloid 
accumulation correlates with cognitive dysfunction in the aged canine. Neurobiology of 
Learning and Memory, 66(1), 11-23. doi:10.1006/nlme.1996.0039 
González-Martínez, Á., Rosado, B., Pesini, P., Suárez, M.L., Santamarina, G., García–
Belenguer, S., . . .  & Sarasa, M. (2011). Plasma β-amyloid peptides in canine aging and 
cognitive dysfunction as a model of Alzheimer's Disease. Experimental Gerontology, 
46(7), 590-596. doi:10.1016/j.exger.2011.02.013 
Head, E. (2013). A canine model of human aging and Alzheimer's Disease. BBA - Molecular 
Basis of Disease, 1832(9), 1384-1389. doi:10.1016/j.bbadis.2013.03.016 
Head, E., Callahan, H., Muggenburg, B.A., Cotman, C.W., & Milgram, N.W. (1998). Visual-
discrimination learning ability and β-amyloid accumulation in the dog. Neurobiology of 
Aging, 19(5), 415-425. doi:10.1016/S0197-4580(98)00084-0 
Head, E., McCleary, R., Hahn, F.F., Milgram, N.W., & Cotman, C.W. (2000). Region-specific 
age at onset of β-amyloid in dogs. Neurobiology of Aging, 21(1), 89-96. 
doi:10.1016/S0197-4580(00)00093-2 
Heath, S.E., Barabas, S., & Craze, P.G. (2007). Nutritional supplementation in cases of Canine 
Cognitive Dysfunction—A clinical trial. Applied Animal Behaviour Science, 105(4), 284-
296. doi:10.1016/j.applanim.2006.11.008 
Madari, A., Farbakova, J., Katina, S., Smolek, T., Novak, P., Weissova, T., . . .  & Zilka, N. 
(2015). Assessment of severity and progression of Canine Cognitive Dysfunction 
syndrome using the CAnine DEmentia Scale (CADES). Applied Animal Behaviour 
Science, 171, 138-145. doi:10.1016/j.applanim.2015.08.034 
29 
CCD AS A REFERENCE FOR AD 
Osella, M.C., Re, G., Odore, R., Girardi, C., Badino, P., Barbero, R., & Bergamasco, L. (2007). 
Canine Cognitive Dysfunction syndrome: Prevalence, clinical signs and treatment with a 
neuroprotective nutraceutical. Applied Animal Behaviour Science, 105(4), 297-310. 
doi:10.1016/j.applanim.2006.11.007 
People for the Ethical Treatment of Animals (PETA). (n.d.). Behind the locked Doors of U.S. and 
French dog laboratories. Retrieved from https://investigations.peta.org/french-dog-
laboratory-animal-testing/ 
Prpar Michevc, S., & Majdič, G. (2019). Canine Cognitive Dysfunction and Alzheimer’s Disease 
– Two facets of the same disease? Frontiers in Neuroscience, 13, 1-18. 
doi:10.3389/fnins.2019.00604 
Schütt, T., Helboe, L., Pederson, L., Waldemar, G., Berendt, M., & Pederson, J.T. (2016).  
Dogs with cognitive dysfunction as a spontaneous model for early Alzheimer's Disease: 
A translational study of neuropathological and inflammatory markers. Journal of 
Alzheimer's Disease, 52(2), 433-49. doi:10.3233/JAD-151085 
Zahs, K. R., & Ashe, K. H. (2013). β-amyloid oligomers in aging and Alzheimer's Disease. 
Frontiers in Aging Neuroscience, 5(28), 1-5. doi:10.3389/fnagi.2013.00028 
 
